FR04C0024I1 - - Google Patents

Info

Publication number
FR04C0024I1
FR04C0024I1 FR04C0024C FR04C0024I1 FR 04C0024 I1 FR04C0024 I1 FR 04C0024I1 FR 04C0024 C FR04C0024 C FR 04C0024C FR 04C0024 I1 FR04C0024 I1 FR 04C0024I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of FR04C0024I1 publication Critical patent/FR04C0024I1/fr
Application filed filed Critical
Application granted granted Critical
Publication of FR04C0024I2 publication Critical patent/FR04C0024I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR04C0024C 1992-11-30 2004-10-22 Active FR04C0024I2 (enrdf_load_html_response)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9203594A SE9203594D0 (sv) 1992-11-30 1992-11-30 Laekemedel i dispersa system
PCT/SE1993/001029 WO1994012153A1 (en) 1992-11-30 1993-11-29 A pharmaceutical formulation

Publications (2)

Publication Number Publication Date
FR04C0024I1 true FR04C0024I1 (enrdf_load_html_response) 2004-03-12
FR04C0024I2 FR04C0024I2 (enrdf_load_html_response) 2010-12-31

Family

ID=20387973

Family Applications (1)

Application Number Title Priority Date Filing Date
FR04C0024C Active FR04C0024I2 (enrdf_load_html_response) 1992-11-30 2004-10-22

Country Status (15)

Country Link
US (1) US5635213A (enrdf_load_html_response)
EP (1) EP0670713B3 (enrdf_load_html_response)
JP (1) JP3661703B2 (enrdf_load_html_response)
AT (1) ATE184191T3 (enrdf_load_html_response)
AU (1) AU688290B2 (enrdf_load_html_response)
CA (1) CA2150464C (enrdf_load_html_response)
DE (2) DE69326350T3 (enrdf_load_html_response)
DK (1) DK0670713T3 (enrdf_load_html_response)
ES (1) ES2137350T7 (enrdf_load_html_response)
FR (1) FR04C0024I2 (enrdf_load_html_response)
GR (1) GR3031988T3 (enrdf_load_html_response)
NL (1) NL300169I1 (enrdf_load_html_response)
NZ (1) NZ258276A (enrdf_load_html_response)
SE (1) SE9203594D0 (enrdf_load_html_response)
WO (1) WO1994012153A1 (enrdf_load_html_response)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
JP4653893B2 (ja) * 2000-01-27 2011-03-16 純一 須藤 二層型経皮吸収製剤
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20050119249A1 (en) * 2003-12-02 2005-06-02 Erik Buntinx Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US8304431B2 (en) * 2003-12-02 2012-11-06 Pharmaneuroboost N.V. Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
ES2351527T3 (es) 2006-05-30 2011-02-07 Intarcia Therapeutics, Inc Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración.
WO2007138086A1 (en) * 2006-05-31 2007-12-06 Solvay Pharmaceuticals Gmbh Long term 24 hour intestinal administration of levodopa/carbidopa
PT2359808E (pt) 2006-08-09 2013-08-28 Intarcia Therapeutics Inc Sistemas de entrega osmótica e montagens de pistão
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
JP5658031B2 (ja) 2007-06-22 2015-01-21 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 薄膜凍結による安定したサブミクロンのペプチド又はタンパク質粒子の形成
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
WO2010056657A2 (en) 2008-11-16 2010-05-20 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
EP3735944A1 (en) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US10335540B2 (en) 2012-04-17 2019-07-02 Micrel Medical Devices S.A. Pharmaceutical blend infusion thereof and Parkinson's disease monitoring system
PL3188725T3 (pl) 2014-09-04 2021-08-02 Lobsor Pharmaceuticals Aktiebolag Kompozycje farmaceutyczne zawierające lewodopę, inhibitor dekarboksylazy dopaminy i inhibitor comt oraz sposób ich podawania
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
RS58972B1 (sr) 2014-10-21 2019-08-30 Abbvie Inc Karbidopa i l-dopa prolekovi i njihova primena za lečenje parkinsonove bolesti
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
WO2016179540A1 (en) 2015-05-06 2016-11-10 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
KR20240037175A (ko) 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP3487479A1 (en) * 2016-07-20 2019-05-29 AbbVie Inc. Levodopa and carbidopa intestinal gel and methods of use
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
MA52122A (fr) 2018-03-02 2021-04-28 Chiesi Farm Spa Formulation pharmaceutique pour administration intraduodénale comprenant de la mélévodopa et de la carbidopa
JP7485874B2 (ja) 2018-03-23 2024-05-17 イントランス・メディカル・システムズ・インコーポレイテッド 神経変性障害の治療のための医薬組成物の連続的投与
TW202031265A (zh) 2018-11-15 2020-09-01 美商艾伯維有限公司 用於皮下投藥之醫藥調配物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
DE2714065A1 (de) * 1977-03-30 1978-10-12 Boehringer Mannheim Gmbh Instillationszubereitung
US4356824A (en) * 1980-07-30 1982-11-02 Vazquez Richard M Multiple lumen gastrostomy tube
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
US4916151A (en) * 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
DE252290T1 (de) * 1986-06-10 1988-06-09 Chiesi Farmaceutici S.P.A., Parma Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
GB8720600D0 (en) * 1987-09-02 1987-10-07 Saad Al Damluji Pharmaceutical compositions
US4863962A (en) * 1988-03-02 1989-09-05 Fidia-Georgetown Institute For The Neurosciences D-DOPA, pharmaceutically acceptable salts thereof, and methods of treating Parkinson's disease
US5326572A (en) * 1989-03-23 1994-07-05 Fmc Corporation Freeze-dried polymer dispersions and the use thereof in preparing sustained-release pharmaceutical compositions
US5266332A (en) * 1991-12-06 1993-11-30 Alza Corporation Method for administering anti-Parkinson drug
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA

Also Published As

Publication number Publication date
ES2137350T7 (es) 2017-11-13
DE69326350T3 (de) 2018-01-11
EP0670713A1 (en) 1995-09-13
WO1994012153A1 (en) 1994-06-09
DE122005000021I1 (de) 2006-02-23
GR3031988T3 (en) 2000-03-31
AU688290B2 (en) 1998-03-12
DE69326350T2 (de) 2000-01-27
CA2150464A1 (en) 1994-06-09
DK0670713T3 (da) 2000-03-20
DE69326350D1 (de) 1999-10-14
AU5583694A (en) 1994-06-22
JP3661703B2 (ja) 2005-06-22
JPH08504764A (ja) 1996-05-21
US5635213A (en) 1997-06-03
EP0670713B1 (en) 1999-09-08
EP0670713B3 (en) 2016-10-05
SE9203594D0 (sv) 1992-11-30
CA2150464C (en) 2002-02-05
FR04C0024I2 (enrdf_load_html_response) 2010-12-31
ATE184191T3 (de) 1999-09-15
NL300169I1 (nl) 2005-03-01
ES2137350T3 (es) 1999-12-16
NZ258276A (en) 1996-09-25

Similar Documents

Publication Publication Date Title
FR2695836B1 (enrdf_load_html_response)
TW221316B (enrdf_load_html_response)
TW239890B (enrdf_load_html_response)
TW247319B (enrdf_load_html_response)
FR04C0024I2 (enrdf_load_html_response)
DK0553875T3 (enrdf_load_html_response)
DK0551248T3 (enrdf_load_html_response)
TW226501B (enrdf_load_html_response)
BR9304651A (enrdf_load_html_response)
TW222276B (enrdf_load_html_response)
DK0574087T3 (enrdf_load_html_response)
DK0576346T3 (enrdf_load_html_response)
TW250500B (enrdf_load_html_response)
BR9207065A (enrdf_load_html_response)
DK0553681T3 (enrdf_load_html_response)
DK0588007T3 (enrdf_load_html_response)
DK0571874T3 (enrdf_load_html_response)
DK0574276T3 (enrdf_load_html_response)
FR2688275B1 (enrdf_load_html_response)
TW266145B (enrdf_load_html_response)
DK0576097T3 (enrdf_load_html_response)
DE9207553U1 (enrdf_load_html_response)
TW216805B (enrdf_load_html_response)
IN185183B (enrdf_load_html_response)
IN186302B (enrdf_load_html_response)